Table 1 Characteristics, first-line antibiotics responses, and second-line treatment responses of HP-negative gastric MALT lymphoma patients.

Case	Sex/Age	Stage	Response	Time to CR	2^nd-line Tx/time to 2^nd-line Tx after diagnosis	Response to 2^nd-line Tx	Relapse	Survival*	Serum IFE**
1	M/54	I	PD		R-COP (6)/12.5 mos	CR	Parotid gland	+106 mos	NA
2	M/53	I	SD		Chlorambucil*/7 mos	SD		+102 mos	NO
3	F/49	I	SD		Chlorambucil/14 mos	CR		+98 mos	NO
4	M/65	I	SD		Chlorambucil/12 mos	CR		+46 mos	IgM/lambda
5	M/48	I	SD		Chlorambucil + Prednisolone/15 mos	CR	Stomach	+94 mos	NO
6	F/33	I	PD		Riuximab/43 mos	SD		+89 mos	NO
7	M/39	I	SD		Radiotherapy/12 mos	CR		+88 mos	NA
8	M/57	I	SD		Radiotherapy/12 mos	CR		+82 mos	NA
9	F/69	I	CR	5 mos				+75 mos	NO
10	F/20	I	SD		Radiotherapy/5 mos	CR		+65 mos	NA
11	F/76	I	CR	12 mos				+64 mos	NO
12	M/76	IIE	SD		Chlorambucil/12 mos	CR		+59 mos	NO
13	M/88	IE	CR	24 mos				+56 mos	NA
14	M/58	I	SD		Observation			+51 mos	NO
15	F/59	I	PR		Observation			+48 mos	NO
16	F/49	I	SD		Chlorambucil/11 mos	CR		+42 mos	NO
17	M/61	I	CR	15 mos				+36 mos	NO
18	M/62	I	PD		R-COP/18 mos	CR		+31 mos	IgM/lambda
19	M/61	I	CR	10 mos				+24 mos	NO
20	M/74	IIE1	SD		Chlorambucil/6 mos	CR		+23 mos	IgM/kappa
21	M/71	I	SD		Chlorambucil/8 mos	CR		+22 mos	NO
22	F/51	I	CR	1 mos				+21 mos	NO
23	F/77	I	CR	4 mos				+20 mos	NO
24	M/48	IIE1	SD		Observation			+18 mos	NO
25	F/32	I	CR	7 mos				+18 mos	NO

Abbreviation: HP, H. pylori; CR, complete remission; Tx, treatment; IFE, immunofixation electrophoresis; M, men; F, women; PD, progressive disease; SD, stable disease; PR, partial remission; mos, months; R, rituximab; COP, cyclophosphamide, vincristine, and prednisolone; NO, no monoclonal gammopathy; NA, no analyses. Case information: Hepatitis B virus carrier, cases #3, #6, #16, and #19; Sicca syndrome, case # 14; Hepatitis C virus infection, case #22. *Survival, alive with follow-up time after treatment (months). **Immunofixation electrophoresis(IFE) showed IgM or IgG monoclonal gammopathy.

Search